Targeting RAF-MEK-ERK kinase-scaffold interactions in cancer

被引：18

作者：

Stuart, Darrin D. ^{[1
]}

Sellers, William R. ^{[2
]}

机构：

[1] Novartis Inst Biomed Res, Emeryville, CA USA

[2] Novartis Inst Biomed Res, Cambridge, MA USA

来源：

NATURE MEDICINE | 2013年 / 19卷 / 05期

关键词：

BRAF; INHIBITION; MELANOMA; MUTATIONS; PHASE-2; IQGAP1;

D O I：

10.1038/nm.3195

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

The RAS-RAF-MEK-ERK signaling kinase pathway has been the focus of intense cancer drug development efforts because of its central role in tumor cell proliferation and survival. Although inhibitors of RAF and MEK provide therapeutic validation, tumor resistance challenges their effectiveness. Targeting scaffolding proteins such as IQGAP1 may be a new approach (pages 626–630).

引用

页码：538 / 540

页数：3

共 50 条

[31] KAP1 inhibits the Raf-MEK-ERK pathway to promote tumorigenesis in A549 lung cancer cells
Wu, Guo-Jin
Pen, Jun
Huang, Ying
An, Su
Liu, Ying
Yang, Yang
Hao, Qian
Guo, Xiao-Xi
Xu, Tian-Rui
MOLECULAR CARCINOGENESIS, 2018, 57 (10) : 1396 - 1407
[32] SIMULTANEOUS TARGETING OF RAF, MEK, AND ERK LIMITS DRUG RESISTANCE
CANCER DISCOVERY, 2017, 7 (09) : 931 - 931
[33] Amplification of wild-type BRAF in melanoma is associated with activation of RAF-MEK-ERK signaling and MEK-dependence
Blumenthal, Ezra
Poulikakos, Poulikos
Tadi, Madhavi
Grbovic-Huezo, Olivera
Taylor, Barry
Janakiraman, Manickam
Leversha, Margaret
Viale, Agnes
Solit, David
Rosen, Neal
Pratilas, Christine
CANCER RESEARCH, 2009, 69
[34] Recent progress in targeting the Raf/MEK/ERK pathway with inhibitors in cancer drug discovery
Thompson, N
Lyons, J
CURRENT OPINION IN PHARMACOLOGY, 2005, 5 (04) : 350 - 356
[35] Targeting RAS/RAF/MEK/ERK signaling in metastatic melanoma
Wang, Ao-Xue
Qi, Xiao-Yi
IUBMB LIFE, 2013, 65 (09) : 748 - 758
[36] Targeting the Ras/Raf/MEK/ERK pathway in hepatocellular carcinoma
Yang, Sufang
Liu, Guohua
ONCOLOGY LETTERS, 2017, 13 (03) : 1041 - 1047
[37] Cancer-related CD15/FUT4 overexpression decreases benefit to agents targeting EGFR or VEGF acting as a novel RAF-MEK-ERK kinase downstream regulator in metastatic colorectal cancer
Guido Giordano
Antonio Febbraro
Eugenio Tomaselli
Maria Lucia Sarnicola
Pietro Parcesepe
Domenico Parente
Nicola Forte
Alessio Fabozzi
Andrea Remo
Andrea Bonetti
Erminia Manfrin
Somayehsadat Ghasemi
Michele Ceccarelli
Luigi Cerulo
Flavia Bazzoni
Massimo Pancione
Journal of Experimental & Clinical Cancer Research, 34
[38] HEPATITIS B VIRUS ANTAGONIZES SORAFENIB IN HEPATOMACELLS THROUGH INDIRECT INDUCTION OF THE RAF-MEK-ERK PATHWAY
Witt-Kehati, D.
Zemel, R.
Shlomai, A.
JOURNAL OF HEPATOLOGY, 2016, 64 : S556 - S556
[39] Cancer-related CD15/FUT4 overexpression decreases benefit to agents targeting EGFR or VEGF acting as a novel RAF-MEK-ERK kinase downstream regulator in metastatic colorectal cancer
Giordano, Guido
Febbraro, Antonio
Tomaselli, Eugenio
Sarnicola, Maria Lucia
Parcesepe, Pietro
Parente, Domenico
Forte, Nicola
Fabozzi, Alessio
Remo, Andrea
Bonetti, Andrea
Manfrin, Erminia
Ghasemi, Somayehsadat
Ceccarelli, Michele
Cerulo, Luigi
Bazzoni, Flavia
Pancione, Massimo
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2015, 34
[40] Inhibition of Raf-MEK-ERK and Hypoxia pathways by Phyllanthus prevents metastasis in human lung (A549) cancer cell line
Sau Har Lee
Indu Bala Jaganath
Rishya Manikam
Shamala Devi Sekaran
BMC Complementary and Alternative Medicine, 13

← 1 2 3 4 5 →